Elliott's Bid Is Good Medicine for a Target


Elliott Management Corp.’s bid for Athenahealth Inc. is a good starting point for buyout talks. 

The hedge fund on Monday released the details of a $6.9 billion takeover offer for the health-care IT company. The bid comes about a year after Elliott disclosed a stake in Athenahealth and sought talks with the board about a potential sale, among other things. That Elliott itself would make an actual offer represents a significant jump in ambition for the private equity side of its business. The bid could be a means of pressuring Jonathan Bush, Athenahealth’s controversial leader and co-founder, to come to the table for deal negotiations. Whether or not Elliott ends up being the eventual buyer, Bush would be wise to capitalize on the opportunity and exit the public market. Athenahealth for now has said it’s reviewing the proposal. 

On the one hand, Elliott’s bid looks opportunistic, coming mere weeks after a post-earnings plunge of about 11 percent as soft bookings in the first quarter made investors skeptical of Athenahealth’s future growth prospects. On the other, Elliott appears to be an investor whose patience is running thin. The firm says it first approached Athenahealth about a buyout in November, but the company refused to engage. Excluding Monday’s pop, the shares have zigged and zagged, but basically gone nowhere in the time since.

Ups and Downs

A buyout may be the best option for Athenahealth

Source: Bloomberg


Athenahealth had committed to a strategic review of its operational and financial strategy in August following Elliott’s criticisms. The company pledged to cut costs and hire an independent chairman. It decided on former General Electric Co. CEO Jeff Immelt, whose operational chops Elliott has questioned, with GE now dealing with the fallout of poor capital allocation decisions made during his tenure and the mismanagement of its power business. 

Demand appears to be slowing for Athenahealth’s main software products for health-care providers, and it’s having a hard time breaking into new markets that are dominated by bigger incumbents like Cerner Corp. and Epic Systems. At the same time, investors are eager to see follow-through on Athenahealth’s cost-cutting initiatives and have been frustrated by management’s inability to hit margin goals. These are the types of issues that tend to be best sorted away from the unforgiving glare of public markets. 

Not Good Enough

Margin improvement has not managed to stop investors from worrying about Athenahealth’s growth slowdown

Source: Bloomberg


Elliott is offering $160 a share in cash, which it says works out to about $6.9 billion including net debt. That’s about 19 times Athenahealth’s estimated Ebitda this year, according to data compiled by Bloomberg, and is a discount to the median multiple paid for medical-information systems takeovers valued at more than $100 million over the past five years. That said, analysts on average were projecting a price of just $143 for Athenahealth’s shares, a target that likely included at least some takeover markup but also expectations for slowing revenue growth over the next few years.

Elliott’s bid may just be the opening gambit. The hedge fund has been expanding the private equity side of its business, completing a $1.6 billion buyout of network-technology company Gigamon Inc. late last year. But the firm has made offers in the past for companies where it’s initially been an investor, before ultimately backing a buyout by an alternative bidder. Elliott bid for Compuware Corp. in 2012 and for Riverbed Technology Inc. in 2014; both were eventually sold to private equity firm Thoma Bravo.



Source link

Leave a Reply

Your email address will not be published.